Global BulletinAll NewsFDA Approval AlertWomen in Oncology
Expert InterviewsAround the PracticeBetween the LinesFace OffFrom All AnglesMeeting of the MindsOncViewPodcastsTraining AcademyTreatment Algorithms with the Oncology BrothersVideos
Conferences
All JournalsEditorial BoardFor AuthorsYear in Review
Frontline ForumSatellite Sessions
CME/CE
Awareness MonthInteractive ToolsNurse Practitioners/Physician's AssistantsPartnersSponsoredSponsored Media
Career CenterSubscribe
Adverse Effects
Brain Cancer
Breast CancerBreast CancerBreast Cancer
Gastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal Cancer
Genitourinary CancersGenitourinary CancersGenitourinary CancersGenitourinary Cancers
Gynecologic CancersGynecologic CancersGynecologic CancersGynecologic Cancers
Head & Neck Cancer
Hematologic OncologyHematologic OncologyHematologic OncologyHematologic Oncology
InfectionInfection
Leukemia
Lung CancerLung CancerLung Cancer
Lymphoma
Neuroendocrine Tumors
Oncology
Pediatric Cancers
Radiation Oncology
Sarcoma
Screening
Skin Cancer & Melanoma
Surgery
Thyroid Cancer
Spotlight -
  • Radiation Oncology
  • Surgery
Adverse Effects
Brain Cancer
Breast CancerBreast CancerBreast Cancer
Gastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal Cancer
Genitourinary CancersGenitourinary CancersGenitourinary CancersGenitourinary Cancers
Gynecologic CancersGynecologic CancersGynecologic CancersGynecologic Cancers
Head & Neck Cancer
Hematologic OncologyHematologic OncologyHematologic OncologyHematologic Oncology
InfectionInfection
Leukemia
Lung CancerLung CancerLung Cancer
Lymphoma
Neuroendocrine Tumors
Oncology
Pediatric Cancers
Radiation Oncology
Sarcoma
Screening
Skin Cancer & Melanoma
Surgery
Thyroid Cancer
    • Conferences
    • CME/CE
    • Career Center
    • Subscribe
Advertisement

FDA Grants Priority Review to Avasopasem for Treatment-Related Oral Mucositis

February 15, 2023
By Russ Conroy
Article

Data from the phase 3 ROMAN trial and the phase 2b GT-201 trial support the new drug application for avasopasem in radiotherapy-induced severe oral mucositis for those with head and neck cancer.

The FDA has accepted and granted priority review to a new drug application for avasopasem manganese (GC4419) for radiotherapy-induced severe oral mucositis in patients with head and neck cancer, according to a press release from Galera Therapeutics.1

With a Prescription Drug User Fee Act date of August 9, 2023, avasopasem may become the first FDA-approved drug for reducing radiotherapy-induced severe oral mucositis in patients with head and neck cancer.

With a Prescription Drug User Fee Act date of August 9, 2023, avasopasem may become the first FDA-approved drug for reducing radiotherapy-induced severe oral mucositis in patients with head and neck cancer.

Currently, there are not any drugs approved by the FDA to reduce severe oral mucositis within this population. The Prescription Drug User Fee Act date has been set for August 9, 2023.

Data from the phase 3 ROMAN trial (NCT03689712) and the phase 2b GT-201 trial (NCT02508389) supported the new drug application for avasopasem, which collectively included a total of 678 patients. Findings from both trials identified clinically meaningful reductions in severe oral mucositis burdens, including a reduced incidence and number of days of severe oral mucositis, incidence of grade 4 oral mucositis, the inability to eat or drink, and delaying time to severe oral mucositis onset.

In the ROMAN trial, avasopasem also reduced cisplatin-induced chronic kidney disease by half after 1 year.

In both trials, patients who received avasopasem plus cisplatin and radiotherapy had similar tumor responses and overall survival as patients in the placebo arms, demonstrating that avasopasem protected patients from severe oral mucositis without affecting the benefit of chemotherapy.

“Avasopasem, if approved, has the potential to reduce pain and suffering for these patients, as well as reduce the costs associated with hospitalizations, surgical placement of feeding tubes, and other treatment burdens,” Mel Sorensen, MD, president and chief executive officer of Galera Therapeutics, said in the press release.

Investigators of the randomized, double-blind, placebo-controlled phase 3 ROMAN trial assessed the capability of avasopasem in reducing radiation-induced severe oral mucositis in 455 patients with locally advanced head and neck cancer. Patients were randomized 3:2 to receive either 90 mg of avasopasem or placebo plus standard-of-care radiotherapy and cisplatin.

The primary end point of the ROMAN trial was incidence of severe oral mucositis, and a secondary end point was duration of severe oral mucositis. Exploratory end points included the time to severe oral mucositis onset and severe oral mucositis incidence at various times during delivery of cumulative radiotherapy.

Investigators of the randomized, double-blind, placebo-controlled phase 2b GT-201 trial assessed avasopasem in 223 patients with locally advanced head and neck cancer. Patients were randomly assigned 1:1:1 to either receive 30 mg or 90 mg of avasopasem or placebo via infusion plus standard-of-care radiotherapy and cisplatin.

One of the primary end points of the GT-201 trial was duration of severe oral mucositis among patients.

In the ROMAN and GT-201 trials, the reported adverse effects (AEs) were consistent with those typically associated with radiotherapy and cisplatin excluding some increases in hypotension and mild nausea with avasopasem. Investigators also highlighted nominal decreases in the rates of some AEs in both trials, including oropharyngeal pain, radiation skin injury, tinnitus, and acute kidney injury.

The FDA previously received the new drug application for avasopasem for the management of radiotherapy-induced severe oral mucositis in head and neck cancer in December 2022.2

References

  1. Galera announces FDA acceptance and priority review of avasopasem NDA for radiotherapy-induced severe oral mucositis. News release. Galera Therapeutics. February 15, 2023. Accessed February 15, 2023. bit.ly/3EbuLfj
  2. Galera submits new drug application for avasopasem for severe oral mucositis. News release. Galera Therapeutics. December 12, 2022. Accessed February 15, 2023. https://bit.ly/3uJlztq

Recent Videos
The phase 3 NIVOSTOP trial evaluated an anti–PD-1 immunotherapy, nivolumab, in a patient population similar in the KEYNOTE-689 trial.
Opportunities to further reduce relapses include pembrolizumab-based combination therapy and evaluating the agent’s contribution before and after surgery.
For patients with locally advanced head and neck cancers, the current standard of care for curative therapy has a cure rate of less than 50%.
The Jack & Sheryl Morris Cancer Center offers “state-of-the-art” surgical suites and advanced radiation technology, says Andrew M. Evens, DO, MBA, MSc.
A study aimed to determine the variables that correlated with extravasation rates in patients receiving radiation injection therapy.
Extravasation with beta emitters may elicit more drastic adverse effects due to their higher radiation dose.
Extravasation results in exposing healthy tissue to radiation, which can be highly dosed depending on the isotope used for treatment.
Related Content
Advertisement

New ASTRO Guidelines Highlight RT in WHO Grade 4 Adult-Type Diffuse Glioma

New ASTRO Guidelines Highlight RT in WHO Grade 4 Adult-Type Diffuse Glioma

Ariana Pelosci
July 6th 2025
Article

Updated guidelines from ASTRO recommend various radiation therapy techniques for patients with WHO grade 4 adult-type diffuse glioma.


A dedicated, well-trained, and expert staff at the Ivy Brain Tumor Center enables the facility to be at the forefront of cutting-edge radiosurgery treatment.

Elucidating Noninvasive Radiosurgery Advancements in CNS Tumors

William R. Kennedy, MD
April 28th 2025
Podcast

A dedicated, well-trained, and expert staff at the Ivy Brain Tumor Center enables the facility to be at the forefront of cutting-edge radiosurgery treatment.


Data support incorporating volumetric PET biomarkers into toxicity risk prediction for patients receiving CAR T-cell therapy for LBCL.

High Tumor Volume Confers CAR T-Cell Therapy Toxicity Risk in LBCL

Russ Conroy
June 30th 2025
Article

Data support incorporating volumetric PET biomarkers into toxicity risk prediction for patients receiving CAR T-cell therapy for LBCL.


Experts from Sibley Memorial Hospital discuss how multidisciplinary work has enhanced outcomes such as survival and resource use at their institution.

Elevating the Quality of Cancer Care via Cross-Department Collaboration

Rachit Kumar, MD;Michael J. Pishvaian, MD, PhD;Nina D. Wagner-Johnston, MD;Valerie Lee, MD;Armine K. Smith, MD;Pouneh Razavi, MD;Curtiland Deville Jr., MD
April 7th 2025
Podcast

Experts from Sibley Memorial Hospital discuss how multidisciplinary work has enhanced outcomes such as survival and resource use at their institution.


Stereotactic online adaptive magnetic resonance guided radiation therapy was well tolerated and maintained stable QOL in patients with PDAC for up to 1 year.

Magnetic Resonance–Guided Radiation May Be Beneficial in Nonmetastatic PDAC

Tim Cortese
June 25th 2025
Article

Stereotactic online adaptive magnetic resonance–guided radiation therapy was well tolerated and maintained stable QOL in patients with PDAC for up to 1 year.


Retrospective analysis at SNMMI 2025 revealed α-FRT with 225AC-3BP-3940 was well tolerated and elicited responses in pretreated metastatic breast cancer.

225AC-3BP-3940 Is Safe, Shows Activity in Heavily Pretreated Advanced Breast Cancer

Gina Mauro
June 24th 2025
Article

Retrospective analysis at SNMMI 2025 revealed α-FRT with 225AC-3BP-3940 was well tolerated and elicited responses in pretreated metastatic breast cancer.

Related Content
Advertisement

New ASTRO Guidelines Highlight RT in WHO Grade 4 Adult-Type Diffuse Glioma

New ASTRO Guidelines Highlight RT in WHO Grade 4 Adult-Type Diffuse Glioma

Ariana Pelosci
July 6th 2025
Article

Updated guidelines from ASTRO recommend various radiation therapy techniques for patients with WHO grade 4 adult-type diffuse glioma.


A dedicated, well-trained, and expert staff at the Ivy Brain Tumor Center enables the facility to be at the forefront of cutting-edge radiosurgery treatment.

Elucidating Noninvasive Radiosurgery Advancements in CNS Tumors

William R. Kennedy, MD
April 28th 2025
Podcast

A dedicated, well-trained, and expert staff at the Ivy Brain Tumor Center enables the facility to be at the forefront of cutting-edge radiosurgery treatment.


Data support incorporating volumetric PET biomarkers into toxicity risk prediction for patients receiving CAR T-cell therapy for LBCL.

High Tumor Volume Confers CAR T-Cell Therapy Toxicity Risk in LBCL

Russ Conroy
June 30th 2025
Article

Data support incorporating volumetric PET biomarkers into toxicity risk prediction for patients receiving CAR T-cell therapy for LBCL.


Experts from Sibley Memorial Hospital discuss how multidisciplinary work has enhanced outcomes such as survival and resource use at their institution.

Elevating the Quality of Cancer Care via Cross-Department Collaboration

Rachit Kumar, MD;Michael J. Pishvaian, MD, PhD;Nina D. Wagner-Johnston, MD;Valerie Lee, MD;Armine K. Smith, MD;Pouneh Razavi, MD;Curtiland Deville Jr., MD
April 7th 2025
Podcast

Experts from Sibley Memorial Hospital discuss how multidisciplinary work has enhanced outcomes such as survival and resource use at their institution.


Stereotactic online adaptive magnetic resonance guided radiation therapy was well tolerated and maintained stable QOL in patients with PDAC for up to 1 year.

Magnetic Resonance–Guided Radiation May Be Beneficial in Nonmetastatic PDAC

Tim Cortese
June 25th 2025
Article

Stereotactic online adaptive magnetic resonance–guided radiation therapy was well tolerated and maintained stable QOL in patients with PDAC for up to 1 year.


Retrospective analysis at SNMMI 2025 revealed α-FRT with 225AC-3BP-3940 was well tolerated and elicited responses in pretreated metastatic breast cancer.

225AC-3BP-3940 Is Safe, Shows Activity in Heavily Pretreated Advanced Breast Cancer

Gina Mauro
June 24th 2025
Article

Retrospective analysis at SNMMI 2025 revealed α-FRT with 225AC-3BP-3940 was well tolerated and elicited responses in pretreated metastatic breast cancer.

Advertisement
About
Advertise
CureToday.com
OncLive.com
OncNursingNews.com
TargetedOnc.com
Editorial
Contact
Terms and Conditions
Privacy
Do Not Sell My Personal Information
Contact Info

2 Commerce Drive
Cranbury, NJ 08512

609-716-7777

© 2025 MJH Life Sciences

All rights reserved.